尿道剂量与前列腺癌放疗后长期患者报告结局的关联
本研究为在三級学术中心开展的预注册横断面研究,纳入连续样本中放疗后至少两年的前列腺癌患者,分析外照射联合高剂量率近距离放疗 boost 后尿道剂量与 EPIC-26 问卷泌尿域长期患者报告结局的关联。单变量分析显示尿道近最大点剂量 DU0.1cc 越高与尿失禁及总体泌尿功能越差相关,预定义多变量分析中 DU0.1cc 与尿失禁仍显著相关,且该关联仅在 DU0.1cc 超过 137 Gy 时存在。作者认为极高的尿道近点剂量似乎与更差的长期患者报告泌尿疾病相关。
要点
- 尿道近最大点剂量 DU0.1cc 越高与 EPIC-26 尿失禁评分越差相关(r=-0.32,p<0.001)。
- 预定义多变量分析中 DU0.1cc 与尿失禁仍显著相关(B=-0.005,p=0.003)。
- 上述关联仅在 DU0.1cc 超过 137 Gy 时存在。
核心结论
- 极高的尿道近点剂量似乎与前列腺癌放疗后更差的长期患者报告泌尿疾病相关。
- 作者认为临床实践和未来试验中应考虑尿道剂量,以潜在减少长期泌尿疾病。
研究设计与样本
- 预注册的横断面研究,在一家三级学术中心纳入放疗后至少两年的连续患者样本。
- 在 277 例筛查患者中,113 例存活、符合条件、知情同意并提供患者报告结局。
- 样本量计算基于预定义多变量模型,p<0.05 视为有统计学意义。
主要发现
- 放疗后中位时间为 4 年。
- 单变量分析中,尿道近最大点剂量 DU0.1cc 越高与 EPIC-26 尿失禁域评分越差相关(r=-0.32;CI=-0.48至-0.13;p<0.001)。
- 单变量分析中,DU0.1cc 越高与 EPIC-26 总体泌尿功能域评分越差相关(r=-0.21;CI=-0.38至-0.03;p=0.02)。
- 预定义多变量分析中,DU0.1cc 与尿失禁仍显著相关(B=-0.005;CI=-0.008至-0.002;p=0.003)。
- 上述关联仅在 DU0.1cc 超过 137 Gy 的极高剂量保留在分析中时存在。
关键数值与推荐
- 主要结局指标为 EPIC-26 问卷的泌尿域。
- 预定义尿道剂量水平与结局的关联采用单变量分析(Pearson 相关)和预定义多变量分析(多元回归)评估。
临床怎么用
- 作者认为临床实践和未来试验中应考虑尿道剂量,以潜在减少长期泌尿疾病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Implications of radiation dose exposure to the urethra on urinary morbidity after prostate radiotherapy are poorly understood, especially by long-term patient-reported outcomes (PRO). Therefore, our primary objective was to investigate associations of urethral dose and long-term patient-reported urinary morbidity after external beam radiotherapy and high-dose rate brachytherapy boost for prostate cancer. MATERIALS AND METHODS: We conducted a pre-registered (https://doi.org/10.17605/OSF.IO/A6DC3) cross-sectional study at a tertiary academic center including a consecutive sample of patients being at least two years after treatment. Primary outcome measurements included urinary domains of the EPIC-26 questionnaire. Their associations with predefined urethral dose levels were assessed by univariable analyses (Pearson's correlation) and by predefined multivariable analyses (multiple regression). Sample size calculation was based on a predefined multivariable model. A p-value < 0.05 was considered statistically significant. RESULTS: Among 277 screened patients, 113 patients were alive, eligible, consented, and provided PRO. The median time passed since radiotherapy was 4 years. Per univariable analysis, a higher near maximum point dose of the urethra (DU0.1cc) was associated with worse urinary incontinence (r = -0.32; CI = -0.48 - -0.13; p < 0.001) and worse overall urinary function (r = -0.21; CI = -0.38 - -0.03; p = 0.02) of the respective EPIC-26 domains. Per predefined multivariable analysis, DU0.1cc and urinary incontinence remained significantly associated (B = -0.005; CI = -0.008 - -0.002; p = 0.003). These associations were only present, when very high DU0.1 cc above 137 Gy were kept in the analysis. CONCLUSIONS: Very high urethral near point doses appear to be associated with worse long-term patient-reported urinary morbidity after radiotherapy for prostate cancer. Urethral dose should be considered in practice and future trials to potentially minimize long-term urinary morbidity. TRIAL REGISTRATION: The study protocol was pre-registered prior to patient accrual on the Open Science Framework (https://doi.org/10.17605/OSF.IO/A6DC3).
引用
- Haack L, Krug D, Domschikowski J, et al. Associations of dose to the urethra and long-term patient-reported outcomes after radiotherapy with EBRT and HDR brachytherapy boost for prostate cancer. Clin Transl Radiat Oncol. 2025. PMID: 39898332. doi:10.1016/j.ctro.2025.100918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。